According to article published in the archives of Neurology research magazine (Arch Neurol. 2010 Feb; 67 (2): 154-60) clinical trial to evaluate the safety and tolerability of Dimebon (latrepirdine) in Huntington’s disease and explore their effects on cognitive function, behavior, and motor symptoms showed positive preliminary results. The clinical trial was a double-blind, multicenter, which participated in 91 patients with mild to moderate Huntington’s disease at 17 centers between United States and England from July 2007 to July 2008. Dimebon (latrepirdine) was administered 20 mgs 3 times a day. Click Nigel Butcher for additional related pages. The primary objective was to assess the tolerability, defined as the ability to complete the assigned dose study, the secondary variable in study included changes in the score from the basal line scale unified of disease of Huntington (UHDRS), the MMSE test and cognitive scale of Alzheimer.
The results obtained were as follows: Dimebon (latrepirdine): was well tolerated (87% of the) patients who manage Dimebon completed the study vs. 82% in the Group placebo control), the rate of adverse events was comparable in the two groups (70% in the Dimebon group) and 80% in the Placebo group. Treatment with Dimebon (latrepirdine) has resulted in an improvement in the average of the score of MMSE test compared with the placebo group. No significant effect in the score from the basal line of scale unified of Huntington disease (UHDRS). Conclusion in this study that the Administration during a short period of Dimebon (latrepirdine) is well tolerated in patients with Huntington’s disease and may have a beneficial effect at the cognitive level, so a trial more big this justified in the population of patients with Huntington’s disease.